FDA approves generic albuterol inhaler for treating bronchospasm
9 April 2020 -

The US Food and Drug Administration (FDA) said on Wednesday that it has authorised the first generic of Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90 mcg/inhalation, to treat and prevent bronchospasm.

This product is intended for patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.

FDA Commissioner Dr Stephen M Hahn said that the agency recognises the increased demand for albuterol products during the COVID-19 pandemic.

The agency granted approval of this generic albuterol sulfate inhalation aerosol to Cipla Limited (NSE:CIPLA).